PRISE-hATGNCT07670650
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 55 words
- Start date changed from estimate of Sep 1, 2026 to Nov 10, 2026
- Secondary endpoints: details revised at 11 of 16 entries
- Study description shortened, about 13 words
- Site details revised at 4 of 4 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)
Timeframe: Dose administration to 12 Months
Secondary (16)
AUC of C-peptide after a 2-hour MMTT in a priori in vitro identified "responders" and "non-responders"
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
To evaluate the pharmacokinetics (PK) of SAB-142
To evaluate the immunogenicity of SAB-142
Immunophenotyping following SAB-142 administration will be performed on PBMC using flowcytometry
Show 11 moreShow less
Haemoglobin A1c (HbA1c) levels
Time in Range (TIR)
Improvement in Time in Tight Range (TITR)
Improvement in Time Below Range on a Continuous Glucose Monitor
Improvement in Time Above Range on a Continuous Glucose Monitor
Number of clinically important hypoglycemic episodes
Exogenous Insulin use
Proportion of participants with partial clinical remission
Proportion of participants with partial remission
Total BETA-2 score
Insulin dose-adjusted A1c (IDAA1C)
Arms and interventions
SAB-142Experimental
SAB-142 in recent and established onset T1D
PlaceboPlacebo comparator
Placebo Comparator
Drugs: SAB-142, Placebo
Sites
4 sites in 1 country